More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain
This article was originally published in The Gray Sheet
Executive Summary
While increasing collaborations between drug and diagnostics companies bode well for the future of companion diagnostics, significant reimbursement and regulatory barriers in Europe continue to vex product developers.